In essence, understanding the molecular mechanisms underlying the antibody-induced cross-linking, deciphering the membrane structures and components governing this event as well as the internalization of PSMA constitute essential prerequisites to understand its role in the most aggressive and metastasizing forms of cancer and for its utilization as a therapeutically suitable target in prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.